Ozempic vs Wegovy: Same Drug, Two Different FDA Approvals

Ozempic and Wegovy are the same active ingredient, semaglutide, made by the same company, Novo Nordisk. The confusion is fair — nothing about the names tells you that. What actually separates them is the FDA paperwork: two different approvals, for two different purposes, at two different maximum doses.

Two approvals, four years apart

Ozempic was approved first, in December 2017, as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes — that is its only FDA-approved use. Wegovy followed in 2021, approved specifically for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition. Same molecule, filed twice, for two different jobs.

The dose ceiling is different

Ozempic's approved maintenance doses top out at 2 mg once weekly. Wegovy's go higher, to 2.4 mg once weekly — a meaningfully larger exposure at the top of the range, which is one reason a diabetes prescription is not a like-for-like substitute for a weight-management one even though the drug in the pen is identical.

Wegovy carries a claim Ozempic doesn't

In March 2024, the FDA approved a label expansion making Wegovy the first weight-management drug approved specifically to reduce the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and obesity or overweight¹. That approval rests on the SELECT trial: 17,604 participants with existing cardiovascular disease and no diabetes, followed for a median of 3+ years, in which Wegovy reduced the composite rate of cardiovascular death, non-fatal heart attack or non-fatal stroke to 6.5% versus 8.0% on placebo². Ozempic does not carry this indication — its own outcomes evidence is in diabetic populations, and in January 2025 the FDA separately approved Ozempic to reduce the risk of kidney disease progression and cardiovascular death specifically in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial³⁴. The two drugs' outcomes claims are approved for different patient populations, and neither claim transfers to the other's label. Both trials, and what they mean beyond the weight-loss numbers, get the full sourced treatment in GLP-1, the heart and the kidneys.

What is actually identical

The molecule, the manufacturer, the general side-effect profile, and the boxed thyroid C-cell tumor warning are the same across both — see the full breakdown in GLP-1 side effects. Off-label prescribing of Ozempic for weight loss happens in practice, but it is prescribing outside the FDA-approved indication, at a lower dose ceiling than the drug purpose-approved for that job.

What this means for a telehealth prescription

A provider dispensing "semaglutide" through a compounding pharmacy is not selling either brand — see compounded vs brand-name GLP-1 for what that distinction actually changes. If brand-name access to either Ozempic or Wegovy specifically matters to you, filter for it on the best semaglutide providers ranking, where brand-name rows are marked. Semaglutide also comes in a third product, the oral tablet Rybelsus — see Rybelsus vs Ozempic for how the same molecule behaves differently by mouth, and Wegovy vs Zepbound if the real decision in front of you is brand-name semaglutide against the competing tirzepatide brand. And if the decision is really between the two molecules rather than the two brand names, semaglutide vs tirzepatide is the comparison that matters — or browse the full research library for the rest of the sourced evidence behind these drugs.